Plant Insulin:
How Corosolic Acid Became the New Focus of Metabolic Health

In the vast landscape of natural product research, few compounds carry both the wisdom of traditional medicine and the validation of modern science quite like Corosolic Acid. This pentacyclic triterpene acid, extracted from the leaves of Lagerstroemia speciosa (Banaba), has earned a striking name in scientific circles – "Plant Insulin" – for its remarkable blood‑sugar‑lowering activity.

What exactly makes it so unique? Let's begin with its molecular identity.

From Banaba Leaf to Bioactive Molecule: Decoding Corosolic Acid

Corosolic Acid is a naturally occurring pentacyclic triterpenoid with the chemical formula C₃₀H₄₈O₄ and a molecular weight of 472.70. It is found primarily in the leaves of Lagerstroemia speciosa (Banaba), and has also been identified in loquat leaves, rhododendron, and various other plants.

In plants, Corosolic Acid often coexists with its isomer maslinic acid. Due to their similar structures and chemical properties, separation is challenging. Modern extraction techniques using column chromatography now enable the production of high‑purity Corosolic Acid white powder – ranging from 80.0% to 99.2% purity – from raw materials such as loquat leaves.

This ability to precisely isolate the compound from complex plant matrices has laid the foundation for deeper research and application of Corosolic Acid.

Metabolic Regulation: The Core Mechanisms of Corosolic Acid

What sets Corosolic Acid apart from other natural compounds is its multi‑target, multi‑pathway metabolic regulatory capacity.

Blood Sugar Lowering: An Insulin‑Like Mode of Action

Research shows that Corosolic Acid promotes glucose transport, enhancing cellular glucose uptake and utilisation, thereby achieving its blood‑sugar‑lowering effect. Its stimulatory effect on glucose transport is similar to that of insulin, hence the name "plant insulin."

In a clinical observation of type‑2 diabetes patients, a Banaba extract standardised to 1% Corosolic Acid produced a 30% reduction in blood glucose levels after two weeks of continuous administration. Corosolic Acid also improves glycaemic control by inhibiting the activity of carbohydrate‑absorbing enzymes such as α‑glucosidase and α‑amylase.

Weight and Lipid Management

A study published in 2008 in Biological and Pharmaceutical Bulletin was the first to confirm Corosolic Acid's potential against obesity and hepatic steatosis. In a KK‑Ay obese mouse model, 9 weeks of 0.023% Corosolic Acid intake resulted in a 10% reduction in body weight and 15% reduction in total fat mass. Fasting glucose, insulin, and triglyceride levels decreased by 23%, 41%, and 22%, respectively.

Research published in 2026 further revealed its molecular mechanisms: Corosolic Acid regulates hepatic de novo lipogenesis by activating the AMPK‑ACC1 axis and inhibiting SCD1, while also promoting cholesterol‑to‑bile‑acid conversion through Slco1b2/SLCO1B1‑mediated hepatic uptake and the FXR‑HMGCR‑CYP7A1 pathway – systematically improving hepatic lipid disorders.

Antioxidant and Anti‑Inflammatory Effects

In a metabolic syndrome rat model (SHR‑cp), 14 weeks of Corosolic Acid treatment resulted in a 10% reduction in blood pressure and a 21% reduction in serum free fatty acids. Oxidative stress markers TBARS and 8‑OHdG decreased by 27% and 59%, respectively, while inflammatory markers 3‑nitrotyrosine and 3‑chlorotyrosine decreased by 38% and 39%.

These data demonstrate that Corosolic Acid acts not only on blood sugar and body weight, but also provides multi‑dimensional protection for metabolic syndrome through antioxidant and anti‑inflammatory mechanisms.

From Lab to Clinic: Depth and Breadth of Research Validation

Research on Corosolic Acid has progressively expanded from cell and animal models to human clinical trials.

In a randomised controlled study registered on ClinicalTrials.gov, 60 postmenopausal women with metabolic syndrome received a combination supplement containing Corosolic Acid, glycyrrhizic acid, and Ceylon cinnamon. Primary outcomes included improvements in blood glucose and insulin levels, triglycerides, HDL cholesterol, and blood pressure.

Preclinical research has also revealed Corosolic Acid's potential in broader fields: its anti‑cancer activity in colon cancer cells manifests as antagonism of the Wnt/β‑catenin pathway; in non‑small cell lung cancer, its regulatory mechanisms on proliferation, invasion, and chemotherapy resistance are also being intensively studied.

In addition, Corosolic Acid has been found to possess antibacterial and antiviral potential, further expanding its application boundaries.

Challenges and Breakthroughs: Solving the Solubility Bottleneck

Despite its exciting biological activities, Corosolic Acid's highly hydrophobic molecular structure leads to poor water solubility and low permeability, significantly limiting its oral bioavailability.

To address this bottleneck, the scientific community is exploring multiple solutions:

• Chemical Structure Modification: Through synthesising Corosolic Acid derivatives, some compounds have achieved α‑glucosidase inhibitory activity twice that of Corosolic Acid. A 2024 study found that derivative H26 outperformed Corosolic Acid in blood sugar reduction, toxicity control, and pharmacokinetic properties, while also revealing MCCC1 as a new target for type‑2 diabetes treatment.
• Microbial Transformation: Utilising microbial biotransformation technology to enhance Corosolic Acid's bioavailability while reducing its toxicity to cancer cells.
• Advanced Delivery Systems: Corosolic Acid‑based nanoformulations have shown significant improvements in solubility, stability, and biological activity.

These technological breakthroughs are progressively unlocking the full potential of Corosolic Acid.

Embracing the Future of Plant Insulin

The story of Corosolic Acid is a perfect convergence of traditional herbal wisdom and modern pharmacological validation. From the Banaba leaf used in Southeast Asian folk medicine for diabetes, to the "plant insulin" now systematically studied by the scientific community, Corosolic Acid has travelled a long and solid road.

It is not a drug, yet it demonstrates drug‑like precision in its mechanisms of action. It is derived from nature, yet it withstands the most rigorous scientific scrutiny. With the gradual overcoming of solubility bottlenecks and the accumulation of more clinical data, Corosolic Acid is moving from a "promising natural product" to an "applicable functional ingredient."